Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Oral insulin may improve liver health in diabetes patients
Last updated July 22, 2026
Key finding
Mean percent reduction in whole-liver fat content was -11.2% in the insulin group.
This study evaluated the safety and potential therapeutic effects of orally delivered insulin in patients with metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus, finding significant reductions in liver fat and fibrosis levels.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the safety and potential therapeutic effects of orally delivered insulin in patients with metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus, finding significant reductions in liver fat and fibrosis levels.
Clinical relevance
The findings highlight the potential of oral insulin as a therapeutic option for patients with metabolic dysfunction-associated steatohepatitis and type 2 diabetes. Reducing liver fat and fibrosis is crucial for preventing further liver damage and improving overall metabolic health, which can lead to better management of diabetes and associated complications.
Keep in mind
The study's sample size and demographic diversity may limit generalizability. Effectiveness of insulin treatment remains unclear due to lack of statistical significance. Long-term effects and safety of oral insulin were not assessed.
Published in
Journal Reference
Publication details and source links for this paper.
Yuval I, Joel N, Yotam K, et al. Safety and potential therapeutic effect of orally delivered insulin in patients with metabolic dysfunction-associated steatohepatitis and type 2 diabetes mellitus. Gastro Hep Advances. 2024;3(3):417-425. doi:10.1016/j.gastha.2023.11.016
Main Effects
Insulin group showed a mean reduction of -11.2% in whole-liver fat content.
Insulin group demonstrated a median reduction of -1.2 kPa in fibrosis levels.
Insulin group had a median reduction of -21.0 dB/m in steatosis levels.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Insulin therapy and Cardiovascular events, Liver fat content, Mean change in Hemoglobin A1c levels after 12 weeks, and 1 more.
This study contributes evidence to
Primary intervention
Insulin therapy
Primary outcomes
- Cardiovascular events
- Liver fat content
- Mean change in Hemoglobin A1c levels after 12 weeks
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
4
Evidence pairs
4
Relationships
2
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 64
2
Related topics
4
Evidence pairs
65
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 4 evidence relationships
- Includes primary outcome data
- Linked to 2 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Insulin Therapies and Cardiovascular Outcomes
Related evidence
Evidence topic
Cardiovascular Risk
Save evidence
Evidence topic
Insulin Therapies
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerMean change in Hemoglobin A1c levels after 12 weeks
Insulin therapy → Mean change in Hemoglobin A1c levels after 12 weeks
Insulin therapy → Mean change in Hemoglobin A1c levels after 12 weeks
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerMedian reduction in fibrosis levels after insulin treatment
Insulin therapy → Median reduction in fibrosis levels after insulin treatment
Insulin therapy → Median reduction in fibrosis levels after insulin treatment
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Oral insulin led to a -11.2% reduction in whole-liver fat content.
- Patients on insulin experienced a -1.2 kPa decrease in fibrosis levels.
- At Week 12, insulin was associated with a -0.27% change in hemoglobin A1c.
Who this applies to
- Adults diagnosed with type 2 diabetes mellitus.
- Patients suffering from metabolic dysfunction-associated steatohepatitis.
Keep in Mind
- Results may not be applicable to populations outside the study's demographic.
- Further research is needed to confirm long-term benefits and safety.
- The study did not establish statistical significance for some outcomes.
Between the Lines
- The study's sample size and demographic diversity may limit generalizability.
- Effectiveness of insulin treatment remains unclear due to lack of statistical significance.
- Long-term effects and safety of oral insulin were not assessed.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Insulin Therapies and Cardiovascular Outcomes, Insulin Therapies and Median reduction in fibrosis levels after insulin treatment.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Insulin Therapies → Cardiovascular Outcomes
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Cardiovascular Outcomes Evidence Hub
All studies measuring Cardiovascular Outcomes
1 studies
outcome_hubMeasures Cardiovascular Outcomes as a key outcome.
Insulin Therapies Evidence Hub
All studies on Insulin Therapies
1 studies
intervention_hubContributes to Insulin Therapies evidence base.
Median reduction in fibrosis levels after insulin treatment Evidence Hub
All studies measuring Median reduction in fibrosis levels after insulin treatment
1 studies
outcome_hubMeasures Median reduction in fibrosis levels after insulin treatment as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Insulin therapy and Cardiovascular events
Intervention: Insulin therapyOutcome: Cardiovascular events
1 results
All studies on Insulin therapy and Median reduction in fibrosis levels after insulin treatment
Intervention: Insulin therapyOutcome: Median reduction in fibrosis levels after insulin treatment
1 results
All studies on Insulin therapy
Intervention: Insulin therapy
1 results
All studies measuring Cardiovascular events
Outcome: Cardiovascular events
1 results
All studies measuring Median reduction in fibrosis levels after insulin treatment
Outcome: Median reduction in fibrosis levels after insulin treatment
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Insulin Therapies improve cardiovascular outcomes?
Emerging Evidence
Insulin Therapies appears to improve Cardiovascular Outcomes.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Cardiovascular events
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Insulin therapy improve liver fat content?
Emerging Evidence
Insulin therapy appears to improve Liver fat content.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Liver fat content
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Insulin therapy improve mean change in hemoglobin a1c levels after 12 weeks?
Emerging Evidence
Insulin therapy appears to improve Mean change in Hemoglobin A1c levels after 12 weeks.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Mean change in Hemoglobin A1c levels after 12 weeks
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Insulin therapy improve median reduction in fibrosis levels after insulin treatment?
Emerging Evidence
Insulin therapy appears to improve Median reduction in fibrosis levels after insulin treatment.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Median reduction in fibrosis levels after insulin treatment
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Semaglutide with Insulin Improves Diabetes Control and Kidney HealthVildagliptin improves glycemic control in type 2 diabetes patients on insulinHybrid Closed-Loop System Reduces Insulin Boluses in Youth with Type 1 DiabetesQCC Model Enhances Diabetes ManagementDynamic insulin algorithm improves glycaemic control in non-critically ill patients
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.